Department of Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Digestive Health Institute, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Clin Liver Dis. 2020 Feb;24(1):107-119. doi: 10.1016/j.cld.2019.09.007.
The hydroxymethyglutaryl-coenzyme A reductase inhibitors (statins) are a commonly prescribed class of medication for the treatment of hyperlipidemia and coronary artery disease. This class of medication has several proven benefits, including reduction of mortality related to coronary artery disease. A major consideration when prescribing these drugs are the potential for adverse effects, mainly myalgias, myopathy, and hepatotoxicity. In this article, we summarize current data on statin-associated hepatotoxicity and highlight that the risk of clinically significant idiosyncratic drug-induced liver injury is actually quite small. We also review preclinical data suggesting potential hepatoprotective effects of statin therapy.
羟甲基戊二酰辅酶 A 还原酶抑制剂（他汀类药物）是一类常用于治疗高脂血症和冠状动脉疾病的药物。这类药物有多项已证实的益处，包括降低与冠状动脉疾病相关的死亡率。在开具这些药物时，主要考虑因素是潜在的不良反应，主要是肌肉疼痛、肌病和肝毒性。本文总结了目前关于他汀类药物相关肝毒性的数据，并强调临床上显著的药物性肝损伤的风险实际上相当小。我们还回顾了提示他汀类药物治疗可能具有肝保护作用的临床前数据。
